Parkinson Disease: Silver DE

  Topic:  
Hints · Remembered Topics    
  Start Here  Overview  World Articles  Find Experts  Books & DVDs  Help 
 
Column View Map 3 Articles   Help
A digest of articles written 1999 and later, on the topic "Parkinson Disease," originating from Planet Earth —» Silver DE.  Display:  All Citations ·  All Abstracts
1 Review Pharmacologic management of Parkinson's disease in long-term care residents: maintaining functionality to improve quality of life. 2007

Silver DE. · No affiliation provided · Director. · Pubmed #19343903 No free full text.

This publication has no abstract.

2 Review Early, nondisabling Parkinson's disease: weighing the options for initial therapy. 2008

Silver DE. · Coastal Neurological Medical Group, Inc., 9850 Genesee Avenue, La Jolla, CA 92037, USA. · Neurol Clin. · Pubmed #18774439 No free full text.

Abstract: This article on treatment of early idiopathic Parkinson's disease (PD) addresses the therapeutic management of the signs and symptoms of PD. It should be read with the understanding that there is more than one way to initiate and manage the early stages of PD.

3 Review Clinical experience with the novel levodopa formulation entacapone + levodopa + carbidopa (Stalevo). 2004

Silver DE. · Coastal Neurological Medical Group, 9850 Genesee Avenue, Suite 740, La Jolla, CA 92037, USA. · Expert Rev Neurother. · Pubmed #15853578 No free full text.

Abstract: Levodopa is the main pharmacologic treatment for Parkinson's disease. However, the long-term administration of levodopa is associated with the development of motor complications which can seriously compromise patient function. Increasing evidence indicates that such problems are related to abnormal pulsatile stimulation of striatal dopamine receptors and that treatments providing more continuous stimulation reduce the risk of motor complications. It is possible that administering levodopa with a reversible catechol-O-methyl transferase inhibitor at frequent intervals might reduce the risk of these complications. Stalevo (Orion) combines levodopa, the dopa-decarboxylase inhibitor carbidopa and the catechol-O-methyl transferase inhibitor entacapone in a single tablet. This review provides an overview of the initial clinical experience gained with Stalevo during clinical trials, including several case studies.